Kistler-Tiffany Companies’s Iovance Biotherapeutics IOVA Stock Holding History

Kistler-Tiffany Companies’s Portfolio IOVA Stock Details IOVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	$1.76K	Hold	250	–	–	﹤0.01%	818
2023 Q1	$1.53K	Hold	250	–	–	﹤0.01%	734
2022 Q4	$1.6K	Hold	250	–	–	﹤0.01%	736
2022 Q3	$2K	Hold	250	–	–	﹤0.01%	732
2022 Q2	$3K	Hold	250	–	–	﹤0.01%	693
2022 Q1	$4K	Hold	250	–	–	﹤0.01%	677
2021 Q4	$5K	Hold	250	–	–	﹤0.01%	650
2021 Q3	$6K	Hold	250	–	–	﹤0.01%	634
2021 Q2	$7K	Buy	+250	New	+$6.5K	﹤0.01%	596

Other funds holding IOVA

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

MFM

MHR Fund Management New York $1.37B AUM 68.35% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

PAMS

Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Kistler-Tiffany Companies's IOVA Position: Q2 2023 in Review

Kistler-Tiffany Companies held its Iovance Biotherapeutics (IOVA) position steady in Q2 2023 at 250 shares worth $1.76K. The position accounts for ﹤0.01% of the portfolio, ranked #818.

Kistler-Tiffany Companies first reported a position in IOVA in Q2 2021 and has held it in 9 quarters since. The position peaked at $7K in Q2 2021. 219 funds tracked by Wall St. Rank hold IOVA as of Q2 2023.

Kistler-Tiffany Companies held 250 shares of Iovance Biotherapeutics worth $1.76K as of Q2 2023.
Kistler-Tiffany Companies left its Iovance Biotherapeutics share count unchanged in Q2 2023.
Iovance Biotherapeutics made up ﹤0.01% of Kistler-Tiffany Companies's portfolio in Q2 2023, its #818 holding.
Kistler-Tiffany Companies first reported a position in Iovance Biotherapeutics in Q2 2021 and has held it in 9 quarters since.
Kistler-Tiffany Companies's Iovance Biotherapeutics position peaked at $7K in Q2 2021.
219 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2023.

Based on Kistler-Tiffany Companies's 13F filing for Q2 2023, filed 1 Aug 2023.